Combination of metformin and parthenolide inhibits breast cancer in mice by apoptosis induction and angiogenesis inhibition - Takeaways - MDSpire

Combination of metformin and parthenolide inhibits breast cancer in mice by apoptosis induction and angiogenesis inhibition

  • By

  • Raghad K. Alomari

  • Moudi M Alasmari

  • Heba K Alshaeri

  • Alexandra Makai

  • Wamidh H Talib

  • Márta Hock

  • June 10, 2026

  • 0 min

Share

  • 1

    Metformin and parthenolide exhibit synergistic antiproliferative effects against breast cancer cell lines in vitro.

  • 2

    Combination therapy of metformin and parthenolide significantly reduces tumor size in vivo, achieving a 50% cure rate.

  • 3

    The combination treatment induces caspase-3-dependent apoptosis and decreases VEGF expression compared to individual agents.

  • 4

    Serum levels of AST, ALT, and creatinine in treated mice remain within normal ranges, indicating safety of the combination.

  • 5

    Further studies are needed to explore the molecular mechanisms and clinical evaluation of the metformin and parthenolide combination.

Original Source(s)

Combination of metformin and parthenolide inhibits breast cancer in mice by apoptosis induction and angiogenesis inhibition

  • by Raghad K. Alomari, Moudi M Alasmari, Heba K Alshaeri, Alexandra Makai, Wamidh H Talib, Márta Hock

  • June 10, 2026

Related Content

Development and validation of an interpretable machine learning model for predicting 5-year recurrence in breast cancer

Barriers, Facilitators, and Intention to Use AI for Breast Cancer Diagnosis: Mixed Methods Study Among Austrian Physicians With and Without AI Experience

Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes